TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Balance Sheet
NASDAQ:TNXP - Nasdaq - US8902608392 - Common Stock - Currency: USD
| MRQ (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 131.72M | 98.78M | 24.95M | 120.20M | 178.70M | |||
| Marketable Securities | N/A | N/A | N/A | N/A | N/A | |||
| Receivables | 3.54M | 4.82M | N/A | N/A | N/A | |||
| Inventories | 8.14M | 8.41M | 13.64M | N/A | N/A | |||
| Other Current Assets | 6.18M | 7.00M | 9.18M | 10.50M | 10.40M | |||
| Total Current Assets | 149.57M | 119.00M | 47.77M | 130.80M | 189.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 42.27M | 42.82M | 94.85M | 94.50M | 51.50M | |||
| Goodwill | N/A | N/A | 965.00K | N/A | N/A | |||
| Intangibles | 120.00K | 120.00K | 9.74M | N/A | 100.00K | |||
| Other Non-Current Assets | 910.00K | 951.00K | 1.13M | 400.00K | 300.00K | |||
| Total Non-Current Assets | 43.30M | 43.89M | 106.69M | 94.90M | 51.90M | |||
| TOTAL ASSETS | 192.87M | 162.89M | 154.46M | 225.70M | 240.90M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 0.00 | 2.82M | 2.35M | N/A | N/A | |||
| Accrued Expenses | 7.95M | 10.94M | 5.37M | 6.20M | 4.90M | |||
| Accounts Payable | 4.19M | 4.55M | 3.78M | 8.10M | 13.30M | |||
| Other Current Liabilities | N/A | N/A | 7.38M | 3.90M | 3.50M | |||
| Total Current Liabilities | 12.15M | 18.31M | 18.88M | 18.20M | 21.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 4.67M | 6.56M | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 328.00K | 358.00K | 23.49M | 300.00K | 500.00K | |||
| Total Non-Current Liabilities | 328.00K | 5.03M | 30.05M | 300.00K | 500.00K | |||
| TOTAL LIABILITIES | 12.47M | 23.33M | 48.93M | 18.50M | 22.20M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -747.52M | -730.69M | -600.66M | -470.00M | -359.80M | |||
| Additional Paid In Capital | 928.18M | 870.50M | 706.36M | 677.30M | 578.10M | |||
| Common Shares | 7.00K | 4.00K | 59.00K | 100.00K | 500.00K | |||
| Other Shareholders' Equity | -266.00K | -255.00K | -232.00K | -200.00K | -100.00K | |||
| Shares Outstanding | 6.88M | 4.39M | 18.30K | 3.80K | 800.00 | |||
| Tangible Book Value per Share | 26.21 | 31.79 | 5.18K | 16.98 | 280.26K | |||
| Total Shareholders' Equity | 180.40M | 139.56M | 105.53M | 207.20M | 218.70M | |||
| TOTAL LIABILITIES AND EQUITY | 192.87M | 162.89M | 154.46M | 225.70M | 240.90M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | 0.03 | 0.06 | N/A | N/A | |||
| Current Ratio | 12.31 | 6.50 | 2.53 | 7.19 | 8.71 | |||
| Return On Assets (ROA) | -68.40% | -79.83% | -75.53% | -51.79% | -38.31% | |||
| Return On Equity (ROE) | -73.13% | -93.18% | -110.55% | -56.41% | -42.20% | |||
All data in USD , ROIC based on taxRate of 0.21